Contrast Media/Contrast Agent Market

Contrast Media/Contrast Agent Market by Type (Iodinated Contrast Media), Modality (X-Ray/CT, MRI, and Ultrasound), Application (Radiology), End User (Hospitals), Indication (Cancer), Route of Administration (Oral), Region - Global Forecast to 2026

Report Code: MD 3577 Jul, 2021, by marketsandmarkets.com

[299 Pages Report] The global contrast media market is projected to reach USD 5.9 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 3.7% during the forecast period. The growth in this market can be attributed to the rising prevalence of chronic diseases, growing approvals of contrast agents, rising volume of CT and MRI examinations performed, growing number of diagnostic centers and hospitals, and availability of reimbursement. Emerging markets in Asian countries are expected to offer strong growth opportunities for players in the market. In contrast, the high cost and inaccessibility of advanced therapeutics may restrict market growth to a certain extent. The contrast media/ contrast agents market is segmented based on type, modality, route of administration, indication, application, end user, and region.

Contrast Media/Contrast Agent Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 impact on the contrast media/ contrast agents market

The COVID-19 outbreak had a negative impact on the contrast media/ contrast agents market due to decreasing patient visits to hospitals. The pandemic has put significant strain on healthcare systems. Healthcare institutes and providers were instructed to stop performing elective surgical procedures and medical examinations to slow the spread of the disease and conserve healthcare resources for COVID-19 patients. As a result, many radiology departments experienced a rapid decline in imaging case volume.

The reduced use of contrast media/ contrast agents due to the declining volume of elective and non-essential procedures, the lower utilization of routine testing, reduced capital spending by customers, and a decrease in research activity due to laboratory closures and reduced clinical testing have all affected the contrast media/ contrast agents market. Many countries have begun to reopen their economies, but it will take time for the utilization rate of contrast media/ contrast agents to reach pre-pandemic levels. Furthermore, any resurgence in COVID-19 infections could result in new lockdowns, quarantine requirements, or other restrictions to slow down the spread of COVID-19, which could negatively impact market growth.

Global Contrast Media/ contrast agents Market Dynamics

DRIVER: Growing approval of contrast agents

The rising global prevalence of chronic diseases has resulted in a significant increase in the demand for diagnostic imaging procedures and, in turn, contrast media. The increasing demand for imaging procedures has resulted in extensive R&D by contrast media manufacturers to launch novel products in the market and to get the contrast media approved in new indications. For instance, in 2021, Bracco received US FDA approval for the 20-vial pack configuration of Lumason, which is an ultrasound contrast agent.

RESTRAINT: Side-effects and allergic reactions associated with contrast agents

Contrast agents are generally considered safe to use in various diagnostic procedures, such as MRI and CT scans. However, certain side-effects and allergic reactions associated with their use may limit market growth to a certain extent. Their adverse reactions range from mild to severe; severe reactions are very uncommon, and serious allergic reactions to contrast materials are rare.

OPPORTUNITY: Generic Contrast Media

In the coming years, competition is expected to intensify greatly in the contrast media market due to the patent expiry of branded contrast media products. This will pave the way for the entry of generic counterparts, which are relatively lower-priced as compared to commercially available branded agents.

In developing countries, APIs are manufactured locally, which brings the overall production costs of manufacturing contrasts agents down. Hence, the patent expiry of various branded products and decreasing costs of manufacturing contrast agents are likely to offer lucrative opportunities for generic players.

CHALLENGE: Dearth of trained professional

A high degree of technical skill and expertise is required to handle advanced and sophisticated diagnostic imaging systems. According to the US Bureau of Labor Statistics, radiology technicians may witness employment growth of about 7% between 2019 and 2029. Although this is significant, the dearth of specialists and radiologists will challenge market growth.

Iodinated Contrast Media segment dominated the Contrast media/ contrast agents market in 2020.

Based on type, the contrast media/ contrast agents market is segmented into iodinated contrast media, gadolinium-based contrast media, microbubble contrast media, and barum-based contrast media. Iodinated contrast media account for the largest share of the contrast media/ contrast agents market. The large share of this segment can be attributed to the growing number of angioplasty procedures performed globally.

The Cardiovascular disorders segment to witness the highest CAGR during the forecast period.

Based on indication, the contrast media/contrast agents market has been segmented into cardiovascular disorders, cancer, gastrointestinal disorders, musculoskeletal disorders, neurological disorders, and nephrological disorders. Cardiovascular disorders accounted for the largest market share and highest growth rate. The large share of this segment can be attributed to the rising geriatric population and the increasing prevalence of CVD across the globe.

North America was the largest regional market for contrast media/ contrast agents market in 2020.

The global contrast media/ contrast agents market is segmented into North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain and the Rest of Europe), Asia Pacific (Japan, China, India, and the Rest of Asia Pacific), Latin America and Middle East & Africa. In 2020, North America dominated the global contrast media/ contrast agents market, followed by Europe. The large share of the North American market can be attributed to the presence of major players in the region, high prevalence of chronic disorders, growing geriatric population, and the increasing adoption of minimally invasive procedures.

Contrast Media/Contrast Agent Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

The prominent players operating in this market include GE Healthcare (US), Bracco Imaging SPA (Italy), Bayer AG (Germany), and Guerbet (France).

Scope of the report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2019

Forecast period

2021–2026

Forecast units

Value (USD Billion)

Segments covered

Type, Modality, Route of Administration, Indication, Application, End User and Region

Geographies covered

North America, Europe, Asia Pacific, and the Rest of the World

Companies covered

GE Healthcare (US), Bracco Imaging SPA (Italy), Bayer AG (Germany), Guerbet (France), Lantheus Medical Imaging, Inc. (US), Unijules Life Sciences (India), J.B. Chemicals and Pharmaceuticals Ltd. (India), SANOCHEMIA Pharmazeutika GmbH (Austria), Taejoon Pharm (South Korea), Jodas Expoim (India), Nano Therapeutics Pvt. Ltd. (India), Kiran X-ray (India), iMax Diagnostic Imaging Limited (Ireland), YZJ Group (China), Livealth Biopharma Pvt. Ltd. (India), Trivitron Healthcare Pvt. Ltd. (India), Novalek Pharmaceuticals Pvt. Ltd. (India), Unispire Biopharma Private Limited (India), Acro Lifesciences (I) Pvt. Ltd. (India), Congruent Pharmachem Private Limited (India), Stanex Drugs & Chemical Pvt. Ltd. (India), Beijing Beilu Pharmaceutical Co., Ltd. (China), Rege Imaging & Cine Films Private Limited (India), K DIAM EXIM (India), Onko έlaη San. ve Tic. A.ή. (Turkey), and Subhra Pharma Pvt. Ltd. (India)

This report categorizes the contrast media/ contrast agents market into the following segments and subsegments

By Type

  • Iodinated Contrast Media
  • Gadolinium-based Contrast Media
  • Microbubble Contrast Media
  • Barium-based Contrast Media

By Modality

  • X-ray/CT
  • MRI
  • Ultrasound

By Route of Administration

  • Intravascular Route
  • Oral Route
  • Rectal Route
  • Other Route of Administration

By Indication

  • Cardiovascular Disorders
  • Cancer
  • Gastrointestinal Disorders
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Nephrological Disorders

By Application

  • Radiology
  • Interventional Radiology
  • Interventional Cardiology

By End User

  • Hospital, Clinics, & Ambulatory Surgery Centers
  • Diagnostic Imaging Centers

By Region

  • North America
  • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Latin America
  • Middle East & Africa

Recent Developments

  • In 2020, GE Healthcare Pharma Limited acquired the ownership of Daiichi Sankyo’s four diagnostic agents in Japan.
  • In 2020, Bracco Imaging SpA received approval from the US FDA for its product ProHance, which is an MRI contrast agent for use in neonates and pediatric patients under two years of age.
  • In 2019, Bayer AG received approval for Gadavist, a gadolinium-based contrast agent used in cardiac MRI for the diagnosis of coronary artery disease.
  • In 2019, Guerbet and InterSystems Corporation (US) entered into the partnership aimed to expand Guerbet’s
  • tion management solution.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 41)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    1.3 MARKET SCOPE
           FIGURE 1 CONTRAST MEDIA/CONTRAST AGENTS MARKET SEGMENTATION
           1.3.1 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 45)
    2.1 RESEARCH DATA
           FIGURE 2 RESEARCH DESIGN
    2.2 SECONDARY DATA
           2.2.1 SECONDARY SOURCES
    2.3 PRIMARY DATA
           FIGURE 3 PRIMARY SOURCES
           2.3.1 KEY DATA FROM PRIMARY SOURCES
           2.3.2 KEY INDUSTRY INSIGHTS
                    FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.4 MARKET SIZE ESTIMATION
           FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
           2.4.1 GROWTH FORECAST
                    FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
                    FIGURE 7 TOP-DOWN APPROACH
    2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.6 MARKET SHARE ANALYSIS
    2.7 ASSUMPTIONS FOR THE STUDY
           2.7.1 COVID-19 SPECIFIC ASSUMPTIONS
    2.8 LIMITATIONS
    2.9 RISK ASSESSMENT
    2.10 GROWTH RATE ASSUMPTIONS
    2.11 COVID-19 ECONOMIC ASSESSMENT
    2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
            FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
            FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY

3 EXECUTIVE SUMMARY (Page No. - 60)
    FIGURE 11 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 12 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2021 VS. 2026 (USD MILLION)
    FIGURE 13 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 14 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 15 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 16 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 17 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 67)
    4.1 CONTRAST MEDIA/CONTRAST AGENTS MARKET OVERVIEW
           FIGURE 18 INCREASING INCIDENCE OF CHRONIC DISORDERS TO DRIVE MARKET GROWTH
    4.2 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE (2021–2026)
           FIGURE 19 MICROBUBBLE CONTRAST MEDIA SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
    4.3 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE AND COUNTRY (2020)
           FIGURE 20 THE US DOMINATED THE NORTH AMERICAN CONTRAST MEDIA/CONTRAST AGENTS MARKET IN 2020
    4.4 CONTRAST MEDIA/CONTRAST AGENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 21 INDIA AND CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 71)
    5.1 INTRODUCTION
           FIGURE 22 CONTRAST MEDIA/CONTRAST AGENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    5.2 MARKET DYNAMICS
           5.2.1 DRIVERS
                    5.2.1.1 Rising prevalence of chronic diseases
                                TABLE 1 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
                    5.2.1.2 Growing approvals of contrast agents
                    5.2.1.3 Rising volume of CT and MRI examinations performed
                                TABLE 2 NUMBER OF MRI EXAMS PERFORMED PER 1,000 INHABITANTS, BY COUNTRY, 2010 VS. 2018
                                TABLE 3 NUMBER OF CT EXAMS PERFORMED PER 1,000 INHABITANTS, BY COUNTRY, 2010 VS. 2018
                    5.2.1.4 Growing number of diagnostic centers and hospitals
                    5.2.1.5 Availability of reimbursement
           5.2.2 RESTRAINTS
                    5.2.2.1 Side-effects and allergic reactions associated with contrast agents
                                TABLE 4 LIST OF SIDE-EFFECTS/REACTIONS TO CONTRAST MEDIA
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Generic contrast media
                    5.2.3.2 Increasing research on contrast agents
                                TABLE 5 INDICATIVE LIST OF RESEARCH STUDIES
           5.2.4 CHALLENGES
                    5.2.4.1 Technological advancements in imaging solutions
                    5.2.4.2 Restriction and withdrawal of linear gadolinium-based contrast agents
                    5.2.4.3 Dearth of trained professionals
                                TABLE 6 METROPOLITAN AREAS IN THE US WITH HIGH EMPLOYMENT LEVELS AMONG RADIOLOGY TECHNOLOGISTS AND TECHNICIANS
    5.3 RANGES/SCENARIOS
           5.3.1 CONTRAST MEDIA/CONTRAST AGENTS MARKET FORECAST
                    FIGURE 23 PESSIMISTIC SCENARIO
                    FIGURE 24 OPTIMISTIC SCENARIO
                    FIGURE 25 REALISTIC SCENARIO
    5.4 COVID-19 IMPACT ON THE CONTRAST MEDIA/CONTRAST AGENTS MARKET
    5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
           5.5.1 REVENUE SHIFT & REVENUE POCKETS FOR CONTRAST MEDIA/CONTRAST AGENT MANUFACTURERS
           5.5.2 REVENUE SHIFT FOR CONTRAST MEDIA/CONTRAST AGENTS MARKET
    5.6 PRICING ANALYSIS
           TABLE 7 PRICES OF CONTRAST MEDIA/CONTRAST AGENTS
    5.7 SUPPLY CHAIN ANALYSIS
           FIGURE 26 DIRECT DISTRIBUTION: A STRATEGY PREFERRED BY PROMINENT COMPANIES
    5.8 VALUE CHAIN ANALYSIS
           FIGURE 27 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE DEVELOPMENT PHASE
    5.9 ECOSYSTEM ANALYSIS
           5.9.1 ROLE IN THE ECOSYSTEM
                    TABLE 8 ROLE OF KEY PLAYERS IN THE ECOSYSTEM
                    FIGURE 28 KEY PLAYERS IN THE CONTRAST MEDIA/CONTRAST AGENTS ECOSYSTEM
    5.10 TECHNOLOGY ANALYSIS
    5.11 PATENT ANALYSIS
    5.12 TRADE ANALYSIS
            TABLE 9 IMPORT DATA FOR OPACIFYING PREPARATIONS FOR X-RAY EXAMINATIONS; DIAGNOSTIC REAGENTS FOR ADMINISTRATION TO PATIENTS, BY COUNTRY, 2016-2020 (USD MILLION)
            TABLE 10 EXPORT DATA FOR OPACIFYING PREPARATIONS FOR X-RAY EXAMINATIONS; DIAGNOSTIC REAGENTS FOR ADMINISTRATION TO PATIENTS, BY COUNTRY, 2016-2020 (USD MILLION)
    5.13 REGULATORY LANDSCAPE
            TABLE 11 LIST OF REGULATORY AUTHORITIES IN THE PHARMACEUTICAL INDUSTRY
           5.13.1 EU REGULATIONS
           5.13.2 FDA REGULATIONS
           5.13.3 JPMA REGULATIONS
    5.14 PORTER’S FIVE FORCES ANALYSIS
            TABLE 12 PORTER’S FIVE FORCES
           5.14.1 INTENSITY OF COMPETITIVE RIVALRY
           5.14.2 BARGAINING POWER OF SUPPLIERS
           5.14.3 BARGAINING POWER OF BUYERS
           5.14.4 THREAT OF SUBSTITUTES
           5.14.5 THREAT OF NEW ENTRANTS

6 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE (Page No. - 95)
    6.1 INTRODUCTION
    6.2 PRIMARY NOTES
           TABLE 13 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
           TABLE 14 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
    6.3 IODINATED CONTRAST MEDIA
           6.3.1 CONSUMPTION OF IODINATED CONTRAST MEDIA IS HIGH DUE TO THE HIGHER DOSAGE REQUIRED IN CT SCANS—A KEY FACTOR DRIVING MARKET GROWTH
                    TABLE 15 IODINATED CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
                    TABLE 16 IODINATED CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
    6.4 GADOLINIUM-BASED CONTRAST MEDIA
           6.4.1 SUSPICION REGARDING THE SAFETY PROFILE OF GADOLINIUM-BASED CONTRAST AGENTS TO CHALLENGE MARKET GROWTH TO A CERTAIN EXTENT
                    TABLE 17 GADOLINIUM-BASED CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
                    TABLE 18 GADOLINIUM-BASED CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
    6.5 MICROBUBBLE CONTRAST MEDIA
           6.5.1 MICROBUBBLES ARE CONVENIENT, COMPLETELY RADIATION-FREE, AND VERSATILE, MAKING THEM EXTREMELY POPULAR WITH PHYSICIANS WORLDWIDE
                    TABLE 19 MICROBUBBLE CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
                    TABLE 20 MICROBUBBLE CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
    6.6 BARIUM-BASED CONTRAST MEDIA
           6.6.1 BARIUM-BASED CONTRAST MEDIA CAN CAUSE ADVERSE EFFECTS IN PATIENTS LIKE PERFORATION OF THE PERITONEUM—THIS IS EXPECTED TO NEGATIVELY IMPACT THE MARKET
                    TABLE 21 BARIUM-BASED CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
                    TABLE 22 BARIUM-BASED CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)

7 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY (Page No. - 104)
    7.1 INTRODUCTION
    7.2 PRIMARY NOTES
           TABLE 23 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
           TABLE 24 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
    7.3 X-RAY/CT
           7.3.1 X-RAY/CT SEGMENT ACCOUNTS FOR THE LARGEST SHARE OF THE CONTRAST MEDIA/CONTRAST AGENTS MARKET
                    TABLE 25 NUMBER OF X-RAY AND CT SCANS IN ENGLAND
                    TABLE 26 INSTALLED BASE OF CT SCANNERS, BY REGION, 2017 VS. 2018
                    TABLE 27 CT PROCEDURAL VOLUMES, BY REGION, 2017 VS. 2018 (MILLION)
                    TABLE 28 X-RAY/CT CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2017–2019 (USD MILLION)
                    TABLE 29 X-RAY/CT CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2020–2026 (USD MILLION)
    7.4 MAGNETIC RESONANCE IMAGING
           7.4.1 GROWING NUMBER OF MRI SCANNERS AND INCREASING MRI EXAMINATIONS ARE DRIVING MARKET GROWTH
                    TABLE 30 INSTALLED BASE OF MRI SYSTEMS, BY REGION, 2017 VS. 2018
                    TABLE 31 MRI PROCEDURAL VOLUMES, BY REGION, 2017 VS. 2018 (MILLION)
                    TABLE 32 NUMBER OF MRI PROCEDURES IN ENGLAND
                    TABLE 33 MRI CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2017–2019 (USD MILLION)
                    TABLE 34 MRI CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2020–2026 (USD MILLION)
    7.5 ULTRASOUND
           7.5.1 ULTRASOUND SEGMENT TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD
                    TABLE 35 NUMBER OF ULTRASOUND PROCEDURES IN ENGLAND
                    TABLE 36 ULTRASOUND CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2017–2019 (USD MILLION)
                    TABLE 37 ULTRASOUND CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2020–2026 (USD MILLION)

8 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 113)
    8.1 INTRODUCTION
           TABLE 38 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
           TABLE 39 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
    8.2 INTRAVASCULAR ROUTE
           8.2.1 WIDESPREAD USE OF INTRAVASCULAR ROUTES OF ADMINISTRATION IN IMAGING MODALITIES TO DRIVE MARKET GROWTH
                    8.2.1.1 INTRAVENOUS (IV) ROUTE
                    8.2.1.2 INTRA-ARTERIAL (IA) ROUTE
                               TABLE 40 INTRAVASCULAR CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
                               TABLE 41 INTRAVASCULAR CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
    8.3 ORAL ROUTE
           8.3.1 USE OF ORAL CONTRAST MEDIA CAN LEAD TO PERFORATIONS IN THE GIT, LEADING TO PERITONITIS—THIS MAY LIMIT MARKET GROWTH TO A CERTAIN EXTENT
                    TABLE 42 ORAL CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
                    TABLE 43 ORAL CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
    8.4 RECTAL ROUTE
           8.4.1 MILD DISCOMFORT ASSOCIATED WITH RECTAL CONTRAST MEDIA TO LIMIT MARKET GROWTH
                    TABLE 44 RECTAL CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
                    TABLE 45 RECTAL CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)
    8.5 OTHER ROUTES OF ADMINISTRATION
           TABLE 46 OTHER CONTRAST MEDIA MARKET, BY REGION, 2017–2019 (USD MILLION)
           TABLE 47 OTHER CONTRAST MEDIA MARKET, BY REGION, 2020–2026 (USD MILLION)

9 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION (Page No. - 121)
    9.1 INTRODUCTION
    9.2 PRIMARY NOTES
           TABLE 48 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
           TABLE 49 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
    9.3 CARDIOVASCULAR DISORDERS
           9.3.1 CARDIOVASCULAR DISORDERS SEGMENT TO DOMINATE THE CONTRAST MEDIA/CONTRAST AGENTS MARKET
                    TABLE 50 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2017–2019 (USD MILLION)
                    TABLE 51 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2020–2026 (USD MILLION)
    9.4 CANCER
           9.4.1 ASIA PACIFIC MARKET TO REGISTER RELATIVELY HIGHER GROWTH OWING TO THE HIGH CANCER PREVALENCE IN THE REGION
                    TABLE 52 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
                    TABLE 53 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR CANCER, BY REGION, 2017–2019 (USD MILLION)
                    TABLE 54 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR CANCER, BY REGION, 2020–2026 (USD MILLION)
    9.5 GASTROINTESTINAL DISORDERS
           9.5.1 RISING PREVALENCE OF GI DISORDERS TO SUPPORT MARKET GROWTH
                    TABLE 55 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2017–2019 (USD MILLION)
                    TABLE 56 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2020–2026 (USD MILLION)
    9.6 MUSCULOSKELETAL DISORDERS
           9.6.1 RISING INCIDENCE OF WORK-RELATED MUSCULOSKELETAL DISORDERS TO SUPPORT MARKET GROWTH
                    TABLE 57 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2017–2019 (USD MILLION)
                    TABLE 58 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2020–2026 (USD MILLION)
    9.7 NEUROLOGICAL DISORDERS
           9.7.1 RISING PREVALENCE OF DEMENTIA TO DRIVE MARKET GROWTH
                    TABLE 59 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2017–2019 (USD MILLION)
                    TABLE 60 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2020–2026 (USD MILLION)
    9.8 NEPHROLOGICAL DISORDERS
           9.8.1 RISING PREVALENCE OF ESRD IS DRIVING THE DEMAND FOR DIAGNOSTIC TOOLS FOR KIDNEY DISEASES
                    TABLE 61 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR NEPHROLOGICAL DISORDERS, BY REGION, 2017–2019 (USD MILLION)
                    TABLE 62 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR NEPHROLOGICAL DISORDERS, BY REGION, 2020–2026 (USD MILLION)

10 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION (Page No. - 132)
     10.1 INTRODUCTION
             TABLE 63 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
             TABLE 64 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
     10.2 RADIOLOGY
             10.2.1 GROWING NUMBER OF DIAGNOSTIC PROCEDURES TO DRIVE THE GROWTH OF THE RADIOLOGY APPLICATIONS SEGMENT
                       TABLE 65 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR RADIOLOGY, BY REGION, 2017–2019 (USD MILLION)
                       TABLE 66 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR RADIOLOGY, BY REGION, 2020–2026 (USD MILLION)
     10.3 INTERVENTIONAL RADIOLOGY
             10.3.1 INCREASING POPULARITY OF MINIMALLY INVASIVE PROCEDURES TO SUPPORT MARKET GROWTH
                       TABLE 67 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR INTERVENTIONAL RADIOLOGY, BY REGION, 2017–2019 (USD MILLION)
                       TABLE 68 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR INTERVENTIONAL RADIOLOGY, BY REGION, 2020–2026 (USD MILLION)
     10.4 INTERVENTIONAL CARDIOLOGY
             10.4.1 RISING INCIDENCE OF CARDIAC DISORDERS TO DRIVE THE DEMAND FOR INTERVENTIONAL CARDIOLOGY PROCEDURES
                       TABLE 69 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR INTERVENTIONAL CARDIOLOGY, BY REGION, 2017–2019 (USD MILLION)
                       TABLE 70 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR INTERVENTIONAL CARDIOLOGY, BY REGION, 2020–2026 (USD MILLION)

11 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER (Page No. - 139)
     11.1 INTRODUCTION
             TABLE 71 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
             TABLE 72 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
     11.2 HOSPITAL, CLINICS, AND AMBULATORY SURGERY CENTERS
             11.2.1 INCREASING ADOPTION OF DIAGNOSTIC IMAGING MODALITIES ACROSS HOSPITALS TO DRIVE MARKET GROWTH
                       TABLE 73 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS, BY REGION, 2017–2019 (USD MILLION)
                       TABLE 74 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR HOSPITALS, CLINICS, AND AMBULATORY SURGERY CENTERS, BY REGION, 2020–2026 (USD MILLION)
     11.3 DIAGNOSTIC IMAGING CENTERS
             11.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO DRIVE MARKET GROWTH IN THE COMING YEARS
                       TABLE 75 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2017–2019 (USD MILLION)
                       TABLE 76 CONTRAST MEDIA/CONTRAST AGENTS MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2020–2026 (USD MILLION)

12 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION (Page No. - 144)
     12.1 INTRODUCTION
             TABLE 77 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2017–2019 (USD MILLION)
             TABLE 78 CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY REGION, 2020–2026 (USD MILLION)
     12.2 NORTH AMERICA
             FIGURE 29 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET SNAPSHOT
             TABLE 79 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
             TABLE 80 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
             TABLE 81 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
             TABLE 82 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
             TABLE 83 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
             TABLE 84 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
             TABLE 85 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
             TABLE 86 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
             TABLE 87 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
             TABLE 88 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
             TABLE 89 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
             TABLE 90 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
             TABLE 91 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
             TABLE 92 NORTH AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
             12.2.1 US
                        12.2.1.1 The US dominates the North American contrast media/contrast agents market
                                     TABLE 93 US: KEY MACROINDICATORS
                                     TABLE 94 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
                                     TABLE 95 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 96 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
                                     TABLE 97 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
                                     TABLE 98 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                                     TABLE 99 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
                                     TABLE 100 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                     TABLE 101 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
                                     TABLE 102 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
                                     TABLE 103 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                                     TABLE 104 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                     TABLE 105 US: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
             12.2.2 CANADA
                        12.2.2.1 Increasing investments in improving medical imaging—a major factor driving market growth in Canada
                                     TABLE 106 CANADA: KEY MACROINDICATORS
                                     TABLE 107 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
                                     TABLE 108 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 109 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
                                     TABLE 110 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
                                     TABLE 111 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                                     TABLE 112 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
                                     TABLE 113 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                     TABLE 114 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
                                     TABLE 115 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
                                     TABLE 116 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                                     TABLE 117 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                     TABLE 118 CANADA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
     12.3 EUROPE
             TABLE 119 TOTAL NUMBER OF MRI UNITS PER 1,000,000 INHABITANTS, 2017
             TABLE 120 TOTAL NUMBER OF MRI EXAMS PER 1,000 INHABITANTS, 2017
             TABLE 121 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
             TABLE 122 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
             TABLE 123 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,  2017–2019 (USD MILLION)
             TABLE 124 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
             TABLE 125 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
             TABLE 126 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
             TABLE 127 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
             TABLE 128 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
             TABLE 129 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
             TABLE 130 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
             TABLE 131 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
             TABLE 132 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
             TABLE 133 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
             TABLE 134 EUROPE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
             12.3.1 GERMANY
                        12.3.1.1 Presence of a well-developed diagnostic imaging infrastructure is a major factor supporting market growth in Germany
                                     TABLE 135 GERMANY: KEY MACROINDICATORS
                                     TABLE 136 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
                                     TABLE 137 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 138 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
                                     TABLE 139 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
                                     TABLE 140 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                                     TABLE 141 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
                                     TABLE 142 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                     TABLE 143 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
                                     TABLE 144 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET,  BY APPLICATION, 2017–2019 (USD MILLION)
                                     TABLE 145 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                                     TABLE 146 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                     TABLE 147 GERMANY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
             12.3.2 UK
                        12.3.2.1 Increasing investments in the field of diagnostic imaging to boost the market growth
                                     TABLE 148 UK: KEY MACROINDICATORS
                                     TABLE 149 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
                                     TABLE 150 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 151 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
                                     TABLE 152 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
                                     TABLE 153 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                                     TABLE 154 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
                                     TABLE 155 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                     TABLE 156 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
                                     TABLE 157 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
                                     TABLE 158 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                                     TABLE 159 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                     TABLE 160 UK: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
             12.3.3 FRANCE
                        12.3.3.1 Increasing prevalence of cancer will drive the market for contrast media in France
                                     TABLE 161 FRANCE: KEY MACROINDICATORS
                                     TABLE 162 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
                                     TABLE 163 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 164 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
                                     TABLE 165 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
                                     TABLE 166 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                                     TABLE 167 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
                                     TABLE 168 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                     TABLE 169 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
                                     TABLE 170 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
                                     TABLE 171 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                                     TABLE 172 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                     TABLE 173 FRANCE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
             12.3.4 SPAIN
                        12.3.4.1 Shortage of radiologists in the country to restrain the market growth
                                     TABLE 174 SPAIN: KEY MACROINDICATORS
                                     TABLE 175 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
                                     TABLE 176 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 177 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
                                     TABLE 178 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
                                     TABLE 179 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                                     TABLE 180 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
                                     TABLE 181 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                     TABLE 182 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
                                     TABLE 183 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
                                     TABLE 184 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                                     TABLE 185 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                     TABLE 186 SPAIN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
             12.3.5 ITALY
                        12.3.5.1 Rising geriatric population likely to drive the demand for diagnostic procedures in Italy
                                     TABLE 187 ITALY: KEY MACROINDICATORS
                                     TABLE 188 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
                                     TABLE 189 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 190 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
                                     TABLE 191 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
                                     TABLE 192 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                                     TABLE 193 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
                                     TABLE 194 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                     TABLE 195 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
                                     TABLE 196 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
                                     TABLE 197 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                                     TABLE 198 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                     TABLE 199 ITALY: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
             12.3.6 REST OF EUROPE
                       TABLE 200 ROE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2018 (% OF GDP)
                       TABLE 201 ROE: NUMBER OF UNITS AND NUMBER OF SCANS, BY COUNTRY, 2018
                       TABLE 202 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
                       TABLE 203 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                       TABLE 204 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
                       TABLE 205 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
                       TABLE 206 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                       TABLE 207 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
                       TABLE 208 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                       TABLE 209 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
                       TABLE 210 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
                       TABLE 211 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                       TABLE 212 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
                       TABLE 213 ROE: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
     12.4 ASIA PACIFIC
             FIGURE 30 ASIA PACIFIC: CONTRAST MEDIA/CONTRAST AGENTS MARKET SNAPSHOT
             TABLE 214 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
             TABLE 215 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY COUNTRY,  2020–2026 (USD MILLION)
             TABLE 216 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
             TABLE 217 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
             TABLE 218 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
             TABLE 219 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
             TABLE 220 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
             TABLE 221 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
             TABLE 222 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
             TABLE 223 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
             TABLE 224 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
             TABLE 225 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
             TABLE 226 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
             TABLE 227 APAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
             12.4.1 JAPAN
                        12.4.1.1 Japan dominates the APAC contrast media/contrast agents market
                                     TABLE 228 JAPAN: KEY MACROINDICATORS
                                     TABLE 229 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
                                     TABLE 230 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 231 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
                                     TABLE 232 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
                                     TABLE 233 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                                     TABLE 234 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
                                     TABLE 235 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                     TABLE 236 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
                                     TABLE 237 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
                                     TABLE 238 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                                     TABLE 239 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                     TABLE 240 JAPAN: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
             12.4.2 CHINA
                        12.4.2.1 High incidence of cancer and strokes will support the market for contrast media in China
                                     TABLE 241 CHINA: KEY MACROINDICATORS
                                     TABLE 242 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
                                     TABLE 243 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 244 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
                                     TABLE 245 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
                                     TABLE 246 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                                     TABLE 247 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
                                     TABLE 248 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                     TABLE 249 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
                                     TABLE 250 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
                                     TABLE 251 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                                     TABLE 252 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                     TABLE 253 CHINA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
             12.4.3 INDIA
                        12.4.3.1 Growing investments in the Indian radiology market will propel market growth
                                     TABLE 254 INDIA: KEY MACROINDICATORS
                                     TABLE 255 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
                                     TABLE 256 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                                     TABLE 257 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
                                     TABLE 258 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
                                     TABLE 259 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                                     TABLE 260 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
                                     TABLE 261 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                     TABLE 262 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
                                     TABLE 263 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
                                     TABLE 264 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                                     TABLE 265 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                     TABLE 266 INDIA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
             12.4.4 REST OF ASIA PACIFIC
                       TABLE 267 NUMBER OF MRI AND CT UNITS PER MILLION POPULATION, PER COUNTRY, 2019
                       TABLE 268 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE,  2017–2019 (USD MILLION)
                       TABLE 269 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                       TABLE 270 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
                       TABLE 271 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
                       TABLE 272 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                       TABLE 273 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
                       TABLE 274 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                       TABLE 275 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
                       TABLE 276 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
                       TABLE 277 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                       TABLE 278 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
                       TABLE 279 ROAPAC: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
     12.5 LATIN AMERICA
             12.5.1 INCREASING HEALTHCARE ACCESS IS EXPECTED TO DRIVE MARKET GROWTH
                       TABLE 280 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
                       TABLE 281 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                       TABLE 282 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
                       TABLE 283 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
                       TABLE 284 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                       TABLE 285 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
                       TABLE 286 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                       TABLE 287 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
                       TABLE 288 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
                       TABLE 289 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                       TABLE 290 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
                       TABLE 291 LATIN AMERICA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)
     12.6 MIDDLE EAST & AFRICA
             12.6.1 POOR REIMBURSEMENT SYSTEMS EXPECTED TO RESTRAIN MARKET GROWTH
                       TABLE 292 ISRAEL: DIAGNOSTIC IMAGING DATA, 2019
                       TABLE 293 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2017–2019 (USD MILLION)
                       TABLE 294 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY TYPE, 2020–2026 (USD MILLION)
                       TABLE 295 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2017–2019 (USD MILLION)
                       TABLE 296 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY MODALITY, 2020–2026 (USD MILLION)
                       TABLE 297 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2017–2019 (USD MILLION)
                       TABLE 298 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2026 (USD MILLION)
                       TABLE 299 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                       TABLE 300 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY INDICATION, 2020–2026 (USD MILLION)
                       TABLE 301 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2017–2019 (USD MILLION)
                       TABLE 302 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
                       TABLE 303 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2017–2019 (USD MILLION)
                       TABLE 304 MEA: CONTRAST MEDIA/CONTRAST AGENTS MARKET, BY END USER, 2020–2026 (USD MILLION)

13 COMPETITIVE LANDSCAPE (Page No. - 234)
     13.1 OVERVIEW
     13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             TABLE 305 OVERVIEW OF STRATEGIES ADOPTED BY KEY CONTRAST MEDIA/CONTRAST AGENTS MARKET PLAYERS
     13.3 MARKET SHARE ANALYSIS
             FIGURE 31 CONTRAST MEDIA/CONTRAST AGENTS MARKET SHARE ANALYSIS, 2020
             TABLE 306 CONTRAST MEDIA/CONTRAST AGENTS MARKET: DEGREE OF COMPETITION (2020)
     13.4 COMPANY EVALUATION QUADRANT
             13.4.1 STARS
             13.4.2 EMERGING LEADERS
             13.4.3 PERVASIVE PLAYERS
             13.4.4 PARTICIPANTS
                       FIGURE 32 CONTRAST MEDIA/CONTRAST AGENTS MARKET: COMPANY EVALUATION QUADRANT, 2020
     13.5 COMPANY EVALUATION QUADRANT: SME/START-UPS
             13.5.1 PROGRESSIVE COMPANIES
             13.5.2 STARTING BLOCKS
             13.5.3 RESPONSIVE COMPANIES
             13.5.4 DYNAMIC COMPANIES
                       FIGURE 33 CONTRAST MEDIA/CONTRAST AGENTS MARKET: COMPANY EVALUATION QUADRANT FOR SME & START-UPS, 2020
     13.6 COMPETITIVE SCENARIO
             FIGURE 34 MARKET EVALUATION MATRIX, 2018–2021
             13.6.1 DEALS
                       TABLE 307 DEALS
             13.6.2 PRODUCT LAUNCHES/APPROVALS
                       TABLE 308 PRODUCT LAUNCHES/APPROVALS
             13.6.3 OTHER DEVELOPMENTS
                       TABLE 309 OTHER DEVELOPMENTS
     13.7 COMPANY FOOTPRINT ANALYSIS
             TABLE 310 COMPANY FOOTPRINT ANALYSIS
             TABLE 311 COMPANY PRODUCT FOOTPRINT
             TABLE 312 COMPANY MODALITY FOOTPRINT
             TABLE 313 COMPANY GEOGRAPHICAL FOOTPRINT

14 COMPANY PROFILES (Page No. - 249)
     14.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             14.1.1 GE HEALTHCARE
                       TABLE 314 GE HEALTHCARE: BUSINESS OVERVIEW
                       FIGURE 35 GE HEALTHCARE: COMPANY SNAPSHOT (2020)
             14.1.2 BRACCO IMAGING SPA
                       TABLE 315 BRACCO IMAGING SPA: BUSINESS OVERVIEW
             14.1.3 BAYER AG
                       TABLE 316 BAYER AG: BUSINESS OVERVIEW
                       FIGURE 36 BAYER AG: COMPANY SNAPSHOT (2020)
             14.1.4 GUERBET
                       TABLE 317 GUERBET: BUSINESS OVERVIEW
                       FIGURE 37 GUERBET: COMPANY SNAPSHOT (2020)
             14.1.5 LANTHEUS MEDICAL IMAGING
                       TABLE 318 LANTHEUS MEDICAL IMAGING: BUSINESS OVERVIEW
                       FIGURE 38 LANTHEUS MEDICAL IMAGING: COMPANY SNAPSHOT (2020)
             14.1.6 UNIJULES LIFE SCIENCES
                       TABLE 319 UNIJULES LIFE SCIENCES: BUSINESS OVERVIEW
             14.1.7 J.B. CHEMICALS AND PHARMACEUTICALS
                       TABLE 320 J.B. CHEMICALS AND PHARMACEUTICALS: BUSINESS OVERVIEW
                       FIGURE 39 J.B. CHEMICALS AND PHARMACEUTICALS LTD: COMPANY SNAPSHOT (2020)
             14.1.8 SANOCHEMIA PHARMAZEUTIKA
                       TABLE 321 SANOCHEMIA PHARMAZEUTIKA: BUSINESS OVERVIEW
             14.1.9 TAEJOON PHARM
                       TABLE 322 TAEJOON PHARM: BUSINESS OVERVIEW
             14.1.10 JODAS EXPOIM
                        TABLE 323 JODAS EXPOIM: BUSINESS OVERVIEW
             14.1.11 NANO THERAPEUTICS
                        TABLE 324 NANO THERAPEUTICS: BUSINESS OVERVIEW
             14.1.12 KIRAN X-RAY
                        TABLE 325 KIRAN X-RAY: BUSINESS OVERVIEW
             14.1.13 IMAX DIAGNOSTIC IMAGING LIMITED
                        TABLE 326 IMAX DIAGNOSTIC IMAGING: BUSINESS OVERVIEW
             14.1.14 YANGTZE RIVER PHARMACEUTICAL GROUP
                        TABLE 327 YZJ GROUP: BUSINESS OVERVIEW
             14.1.15 LIVEALTH BIOPHARMA
                        TABLE 328 LIVEALTH BIOPHARMA: BUSINESS OVERVIEW
     14.2 OTHER PLAYERS
             14.2.1 TRIVITRON HEALTHCARE
             14.2.2 NOVALEK PHARMACEUTICALS
             14.2.3 UNISPIRE BIOPHARMA PRIVATE LIMITED
             14.2.4 ARCO LIFESCIENCES
             14.2.5 CONGRUENT PHARMACHEM PRIVATE LIMITED
             14.2.6 STANEX DRUGS & CHEMICAL
             14.2.7 BEIJING BEILU PHARMACEUTICAL
             14.2.8 REGE IMAGING & CINE FILMS
             14.2.9 K DIAM EXIM
             14.2.10 ONKO έLAΗ SAN. VE TIC. A.ή.
             14.2.11 SUBHRA PHARMA

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX (Page No. - 291)
     15.1 INSIGHTS FROM INDUSTRY EXPERTS
     15.2 DISCUSSION GUIDE
     15.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     15.4 AVAILABLE CUSTOMIZATIONS
     15.5 RELATED REPORTS
     15.6 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the contrast media/ contrast agents market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the contrast media/ contrast agents market. The secondary sources used for this study include  European Society of Radiology (ESR), Society of Interventional Radiology (SIR), Asia Pacific Society of Cardiovascular and Interventional Radiology (APSCVIR), American College of Radiology (ACR), Organisation for Economic Co-operation and Development (OECD), International Society of Radiology (ISR), Radiological Society of North America (RSNA), Journal of Radiology, National Institutes of Health (NIH), International Life Sciences Institute (ILSI), National Kidney Foundation (NKF), American Association for Cancer Research (AACR), US Food and Drug Administration (US FDA), American Medical Association (AMA), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), Eurostat, SEC Filings, Annual Reports, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Contrast Media/Contrast Agent Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the contrast media/ contrast agents market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the contrast media/ contrast agents business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global contrast media/ contarst agents market based on the type, procedure, application and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall contrast media/ contarst agents market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America and the Middle East & Africa
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the contrast media/ contrast agents market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional five company profiles
COVID-19

Get in-depth analysis of the COVID-19 impact on the Contrast Media/Contrast Agent Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Contrast Media/Contrast Agent Market

Request For Special Pricing
Report Code
MD 3577
Published ON
Jul, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Contrast Media/Contrast Agent Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved